Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
29.45
+1.21 (4.36%)
Market open: Aug 12, 2026, 3:40 PM EDT
29.82
+1.58 (5.61%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
| Name | Position |
|---|---|
| Dr. Daniel G. Baker M.D., Ph.D. | Interim Chief Development Officer |
| Dr. Rodolfo Jose Chaparro Ph.D. | Co-Founder |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder |
| Dr. Shao-Lee Lin M.D., Ph.D. | President, CEO & Director |
| Dr. Steven C. Almo Ph.D. | Co-Founder and Chairman of Scientific & Clinical Advisory Board |
| Mr. Colin G. Sandercock J.D., MSE | Senior Vice President of Intellectual Property |
| Mr. James M. Ahlers | Chief Financial Officer |
| Ms. Agnes Lee | Chief Officer of Public & Investor Relations |
| Ms. Lucinda Warren | Principal Accounting Officer & Chief Business Officer |
| Ms. Sumita Ray J.D. | Chief Legal & Compliance Officer and Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-08-03 | 8-K | d134183d8k.htm |
| 2026-07-22 | D | |
| 2026-07-10 | 8-K | d123955d8k.htm |
| 2026-06-18 | S-3 | d44856ds3.htm |
| 2026-06-03 | S-8 | d107767ds8.htm |
| 2026-06-03 | 8-K | cue-20260601.htm |
| 2026-06-02 | 8-K | d139032d8k.htm |
| 2026-05-21 | DEF 14A | d38874ddef14a.htm |
| 2026-05-14 | D | |
| 2026-05-14 | 10-Q | cue-20260331.htm |